Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial

The cell and gene therapy product AGT103-T was designed to restore the Gag-specific CD4+ T cell response in persons with chronic HIV disease who are receiving antiretroviral therapy. This autologous, genetically engineered cell product is under investigation in a Phase 1 clinical trial (NCT03215004)...

Descripción completa

Detalles Bibliográficos
Autores principales: Muvarak, Nidal, Li, Haishan, Lahusen, Tyler, Galvin, Jeffrey A., Kumar, Princy N., Pauza, C. David, Bordon, José
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701732/
https://www.ncbi.nlm.nih.gov/pubmed/36452901
http://dx.doi.org/10.3389/fmed.2022.1044713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701732/
https://www.ncbi.nlm.nih.gov/pubmed/36452901
http://dx.doi.org/10.3389/fmed.2022.1044713

Ejemplares similares